

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

VOLUNTARY ANNOUNCEMENT –
ZHAOKE OPHTHALMOLOGY’S MANUFACTURING FACILITY
OBTAINS GMP CERTIFICATION FROM THE THERAPEUTIC GOODS
ADMINISTRATION OF AUSTRALIA (“TGA”)

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that the Company’s manufacturing facility located in Nansha, Guangzhou, China has recently obtained Good Manufacturing Practice (“**GMP**”) certification issued by the Therapeutic Goods Administration of Australia (“**TGA**”).

Australia is an official member of the Pharmaceutical Inspection Co-operation Scheme (“**PIC/S**”), and its GMP inspection results enjoy a high degree of mutual recognition among PIC/S member authorities. The TGA GMP certification represents further recognition by an international pharmaceutical regulatory authority of the manufacturing and quality management systems of the Company’s manufacturing facility. As multiple products continue to advance through overseas registration and commercialization, the Company’s manufacturing and quality management systems that comply with international regulatory requirements will provide important support for the future entry of the relevant products into more overseas markets and the Company’s continued advancement of its globalization strategy.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop or commercialize the relevant products successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, October 27, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.